Five-year EFS
| . | No. of patients . | All, % . | RER, % . | SER, % . |
|---|---|---|---|---|
| All | 216 | 84 (± 3) | 86 (± 3) | 83 (± 4) |
| Intermediate risk | 53 | 84 (± 5) | 82 (± 6) | 88 (± 8) |
| Stage IB* | 1 | — | — | — |
| Stage IIA | 34 | 78 (± 8) | — | — |
| Stage IIIA | 18 | 94 (± 5) | — | — |
| High risk | 163 | 85 (± 3) | 88 (± 3) | 82 (± 5) |
| Stage IIB | 49 | 92 (± 4) | — | — |
| Stage IIIB | 37 | 92 (± 6) | — | — |
| Stage IVA | 26 | 81 (± 8) | — | — |
| Stage IVB | 51 | 74 (± 6) | — | — |
| “B” symptoms | ||||
| Yes | 78 | 83 (± 4) | 84 (± 6) | 83 (± 7) |
| No | 138 | 85 (± 3) | 87 (± 4) | 84 (± 5) |
| LMA | ||||
| Yes | 125 | 80 (± 4) | 81 (± 5) | 80 (± 6) |
| No | 79 | 91 (± 3) | 94 (± 4) | 86 (± 6) |
| Dexrazoxane | ||||
| Yes | 107 | 83 (± 4) | 89 (± 4) | 78 (± 6) |
| No | 109 | 86 (± 3) | 84 (± 4) | 91 (± 5) |
| . | No. of patients . | All, % . | RER, % . | SER, % . |
|---|---|---|---|---|
| All | 216 | 84 (± 3) | 86 (± 3) | 83 (± 4) |
| Intermediate risk | 53 | 84 (± 5) | 82 (± 6) | 88 (± 8) |
| Stage IB* | 1 | — | — | — |
| Stage IIA | 34 | 78 (± 8) | — | — |
| Stage IIIA | 18 | 94 (± 5) | — | — |
| High risk | 163 | 85 (± 3) | 88 (± 3) | 82 (± 5) |
| Stage IIB | 49 | 92 (± 4) | — | — |
| Stage IIIB | 37 | 92 (± 6) | — | — |
| Stage IVA | 26 | 81 (± 8) | — | — |
| Stage IVB | 51 | 74 (± 6) | — | — |
| “B” symptoms | ||||
| Yes | 78 | 83 (± 4) | 84 (± 6) | 83 (± 7) |
| No | 138 | 85 (± 3) | 87 (± 4) | 84 (± 5) |
| LMA | ||||
| Yes | 125 | 80 (± 4) | 81 (± 5) | 80 (± 6) |
| No | 79 | 91 (± 3) | 94 (± 4) | 86 (± 6) |
| Dexrazoxane | ||||
| Yes | 107 | 83 (± 4) | 89 (± 4) | 78 (± 6) |
| No | 109 | 86 (± 3) | 84 (± 4) | 91 (± 5) |
Values are mean (± SE).
— indicates not analyzed.
Did not report EFS for stage IB because only 1 patient was in the stratum.